Accelerate Diagnostics down on discontinuation of blood test device in U.S.

Accelerate Diagnostics

21/10/2022 22:09

** Shares of Accelerate Diagnostics Inc  AXDX.O  fall 32.5%
to $1.06 - biggest loser across U.S. stock exchanges after
market
    ** Co says FDA has discontinued marketing of its medical
device accelerate arc for blood diagnostics in U.S. - SEC filing
    ** FDA has asked co to file an marketing application for the
device, which was previously listed as class I device, which are
devices that are low to moderate risk to patients, and exempted
from the requirement
    ** As of last close, stock down ~70% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))